Navigation Links
NovaBay(R) Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference September 10, 2009 in New York City
Date:9/3/2009

EMERYVILLE, Calif., Sept. 3 /PRNewswire-FirstCall/ -- NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY,http://www.novabaypharma.com), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will present at the Rodman & Renshaw 11th Annual Healthcare Conference at 10 a.m., Thursday, Sept. 10, 2009 at the New York Palace Hotel in New York City.

This presentation will also be made available via webcast athttp://www.wsw.com/webcast/rrshq15/.

Dr. Najafi will provide a corporate overview and highlight NovaBay's clinical progress, business development strategy and product development candidates. His presentation will:

  • Update investors on NovaBay's internal clinical programs in hospital-associated infections and respiratory infections.
  • Provide information on NovaBay's recent announcements regarding the initiation of a Phase II clinical trial for the use of NovaBay's lead Aganocide((R)) compound, NVC-422, for viral conjunctivitis, which is being conducted by its partner Alcon (NYSE: ACL).
  • Review the partnership with Galderma, the world's leading dermatology company, for development of acne and impetigo products.
  • Discuss the collaborative agreements with professors Markus Nagl, M.D. and Waldemar Gottardi, Ph.D. of the Medical University of Innsbruck, Austria, which broaden NovaBay's intellectual property estate, expand its pre-clinical pipeline and advance the development of NovaBay's Aganocide((R)) compounds by integrating on-going clinical work at the Medical University of Innsbruck with NovaBay's development programs.

About Aganocide((R)) Compounds

The Aganocide((R)) compounds are novel, proprietary, synthetic N-chlorinated antimicrobial molecules specifically developed by NovaBay((R)) to mimic the body's natural defense against infection. The Aganocide((R)) compounds maintain the biological activities while improving the stability of naturally occurring N-chlorinated antimicrobial molecules. These highly differentiated, first-in-class, small-molecule, patented new chemical entities may be able to deliver the same or better efficacy than currently used antibiotics without contributing to the growing rise of antibiotic-resistant bacterial strains. In preclinical testing, the Aganocide((R)) compounds have been shown to be highly effective against bacteria, including multi-drug resistant strains, viruses and fungi. They also have been demonstrated to be effective against bacteria in biofilms, which render most antibiotics ineffective. Aganocides have a broad therapeutic index while providing a high degree of potency and tolerability as well as dosing versatility and flexibility.

About NovaBay

NovaBay((R)) Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing its proprietary and patented Aganocide((R)) compounds, which are novel, synthetic, anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay((R)) has internal development programs aimed at addressing dermatological, hospital and respiratory infections. The company has a licensing and research collaboration agreement with Alcon, Inc. for use of its Aganocide((R)) compounds to treat eye, ear and sinus infections as well as in contact lens care solutions. NovaBay((R)) has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. For more information on NovaBay, visit: www.novabaypharma.com.


'/>"/>
SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
2. NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
3. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
4. Arena Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
5. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
6. Onyx Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
7. Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16, 2009
8. Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
9. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
10. Jiangbo Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
11. Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
Breaking Biology News(10 mins):